Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment

Clinical and Experimental Metastasis

Volumn 32, Issue 4, 2015, Pages 335-344

  Sosnoski, Donna M ^a   Norgard, Robert J ^a   Grove, Cassidy D ^a   Foster, Shelby J ^a   Mastro, Andrea M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Bone metastases; Breast cancer; Dormancy; Prostaglandins; Three dimensional bioreactor

Indexed keywords

FIBROBLAST GROWTH FACTOR; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE REMODELING; BONE TUMOR; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; HUMAN; MCF 7 CELL LINE; MOUSE; OSTEOBLAST; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

3T3 CELLS; ANIMALS; BONE NEOPLASMS; BONE REMODELING; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INDOMETHACIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MCF-7 CELLS; MICE; OSTEOBLASTS; RECEPTORS, PROSTAGLANDIN E; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930892096     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9710-9     Document Type: Article

References (54)

1. DeSantis C et al (2013) Breast cancer statistics, 2013. Cancer J Clin 64(1):52–62
2. Klein CA (2011) Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 21(1):42–49
3. Demicheli R et al (2007) Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4(12):699–710
4. Lipton A et al (2009) The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Cancer Netw 7(Suppl 7):S1–S29 quiz S30
5. Rubens RD (2000) Bone metastases–incidence and complications. In: Rubens RD, Mundy GR (eds) Cancer and the skeleton. Martin Dunitz, London 286
6. Naumov GN, Folkman J, Straume O (2009) Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis 26(1):51–60
7. Demicheli R et al (2008) Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 10(5):R83
8. Aguirre-Ghiso JA, Bragado P, Sosa MS (2013) Metastasis awakening: targeting dormant cancer. Nat Med 19(3):276–277
9. Weiss L (1990) Metastatic inefficiency. Adv Cancer Res 54:159–211
10. Pantel K et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85(17):1419–1424
11. Hedley BD, Chambers AF (2009) Tumor dormancy and metastasis. Adv Cancer Res 102:67–101
12. Takeuchi H, Muto Y, Tashiro H (2009) Clinicopathological characteristics of recurrence more than 10 years after surgery in patients with breast carcinoma. Anticancer Res 29(8):3445–3448
13. Pantel K et al (2003) Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9(17):6326–6334
14. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340
15. Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544
16. Das Roy L et al (2009) Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res 11(4):R56
17. Yano S (2014) Metastatic bone lesion due to methotrexate and etanercept 24 years after breast cancer treatment. BMJ Case Rep. doi:10.1136/bcr-2013-202615
18. Rotolo N et al (2013) Metastasis at a tracheostomy site as the presenting sign of late recurrent breast cancer. Head Neck 35(11):E359–E362
19. Demicheli R et al (2008) The effects of surgery on tumor growth: a century of investigations. Ann Oncol 19(11):1821–1828
20. Schneider A et al (2005) Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146(4):1727–1736
21. Tashjian AH Jr, Gagel RF (2006) Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21(3):354–365
22. Mundy GR et al (2008) Cytokines and bone remodeling. In: Marus R et al (eds) Osteoporosis. Editors Academic Press, New York, pp 491–528
23. Dhurjati R et al (2006) Extended-term culture of bone cells in a compartmentalized bioreactor. Tissue Eng 12(11):3045–3054
24. Cailleau R, Olive M, Cruciger QV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14:911–915
25. Mastro AM, Vogler EA (2009) A three-dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. Cancer Res 69(10):4097
26. Phillips KK et al (1996) Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer Res 56(6):1222–1227
27. Krishnan V et al (2011) Dynamic interaction between breast cancer cells and osteoblastic tissue: comparison of two- and three-dimensional cultures. J Cell Physiol 226(8):2150–2158
28. Phadke PA et al (2008) BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 172(3):809–817
29. Sosnoski DM et al (2012) Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast Cancer 2012:160265
30. Wang H et al (1997) Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 57(9):1750–1757
31. Sato K et al (1986) Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun 138(2):618–624
32. Sato K et al (1987) Tumor necrosis factor type alpha (cachectin) stimulates mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2. Biochem Biophys Res Commun 145(1):323–329
33. Bai X et al (2013) Prostaglandin E(2) receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol 42(5):1833–1841
34. Sudo H et al (1983) In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96(1):191–198
35. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675
36. Pilbeam CC, Harrison JR, Raisz LG (2002) Prostaglandins and bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, New York
37. Mundy GR et al (2001) Cytokines and bone remodeling. In: Marcus RE, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, New York, pp 373–403
38. Mark KS, Trickler WJ, Miller DW (2001) Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 297(3):1051–1058
39. Ono M (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8):1501–1506
40. Oshima H, Oshima M (2012) The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol 47(2):97–106
41. Najmi S et al (2005) Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin Cancer Res 11(5):2038–2046
42. Phadke PA, Mercer RR, Harms JF, Jia Y, Kappes JC, Frost AR, Jewell JL, Bussard KM, Nelson S, Moore C, Gay CV, Mastro AM, Welch DR (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12:1431–1440
43. Blackwell KA, Raisz LG, Pilbeam CC (2010) Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 21(5):294–301
44. Ristimaki A et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632–635
45. Singh B et al (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789–3796
46. Schrey MP, Patel KV (1995) Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72(6):1412–1419
47. Cicek M et al (2005) Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 65(9):3586–3595
48. Klein DC, Raisz LG (1970) Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 86(6):1436–1440
49. Planchon P et al (1995) Evidence for separate mechanisms of antiproliferative action of indomethacin and prostaglandin on MCF-7 breast cancer cells. Life Sci 57(12):1233–1240
50. Sosa MS, Bragado P, Aguirre-Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14(9):611–622
51. Wilson A, Trumpp A (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6:93–106
52. Shiozawa Y et al (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22(5):941–950
53. Mirza AA et al (2014) MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells. Biochim Biophys Acta 1843(5):945–954
54. Khoon MCS (2015) Experimental models of bone metastasis: opportunities for the study of cancer dormancy. Adv Deliv Rev. doi:10.1016/j.addr.2015.02.007